IBEC researchers appear in different media for the recent study senior-authored by Joan Montero and first-authored by Albert Manzano, Senior Researcher and PhD student in IBEC’s Nanobioengineering group in which they have used a state-of-the-art analysis technique to evaluate new drug combinations to successfully treat acute lymphoblastic leukemia.
The study published in the scientific journal Frontiers in Cell and Developmental Biology addresses an urgent need to develop more personalised therapies that cater to each patient, while reducing the side effects often brought on by a “one size fits all” approach to treatment.
We hope that this and future studies in our lab can help pediatric leukemia patients achieve recovery with minimum possible adverse side effects.
Joan Montero, IBEC.
You can read the impacts in the media here: